M1 Kliniken AG

  • WKN: A0STSQ
  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 18.12.2018 | 08:00

M1 Kliniken AG starts international expansion: Specialist Centre for Aesthetic Medicine opened in Vienna

DGAP-News: M1 Kliniken AG / Key word(s): Expansion

18.12.2018 / 08:00
The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG starts international expansion: Specialist Centre for Aesthetic Medicine opened in Vienna

- Market leader for beauty medicine in Germany sees a strong growth in Europe's attractive growth opportunities
- Potential for up to 10 locations in Austria and Switzerland alone
- More than 20 specialist centres to be opened in Europe by the end of 2020

Berlin, 18.12.2018 - M1 Kliniken AG (ISIN: DE000A0STSQ8), market leader in the field of beauty medicine in Germany, has opened the first "M1 Med Beauty" specialist centre outside its home market in Vienna. In the Austrian capital, M1's experienced specialists are now available for all aspects of aesthetic medicine. The M1 Group has thus begun its international expansion. Numerous countries in Europe offer attractive growth opportunities. The number of M1 Beauty specialist centres is to be more than doubled from the current 24 to 50 by the end of 2020. At least 20 locations are planned in Europe.

"Similar to Germany, the markets for beauty medicine are highly fragmented and expensive in virtually all Western European countries. Having developed M1 into the market leader in Germany in just a few years, we want to take advantage of the attractive environment and grow significantly in Europe in the future," says Patrick Brenske, Member of the Management Board of M1 Kliniken AG.

High treatment quality with low costs at the same time due to specialization
Since the beginning of its expansion in 2015, the M1 Group has been the first company in the industry to focus on specialization. The advantage: high treatment quality at low costs. Centralized purchasing enables the use of state-of-the-art technical infrastructure and top-quality products at a low price. In addition, a high utilization of the premises and the medical technology is achieved. M1 passes on these cost advantages - which will increase even more as the company grows - to its customers and at the same time maintains high medical quality. For example, M1 has founded its own academy for the further training of its now more than 60 employeed doctors. This is rewarded by the customers: In 2017, around 70 percent of customers were not with M1 for the first time.

More than 20 specialist centres planned throughout Europe by the end of 2020
Now that M1 has successfully completed the extensive approval procedure for the Vienna location, the opening of further locations in Austria is planned. In addition, the focus in the coming years will be on Switzerland, the Netherlands and Great Britain. In all countries, M1 will make high-quality aesthetic medicine available to a larger population group at attractive prices and thus increase market volumes. A total of more than 20 specialist centres for aesthetic medicine are to be opened in European countries outside Germany by the end of 2020. M1 has already secured financing for its international expansion through a capital increase carried out in September 2018. This also applies to growth financing in Germany. In addition to other M1 Med Beauty locations, the Group has already prepared for expansion into the areas of aesthetic dentistry and laser treatment under the new "M1 Dental" and "M1 Laser" brands.

About M1 Kliniken AG
M1 Kliniken AG (ISIN: DE000A0STSQ8, stock exchange symbol: M12) is the leading private provider of beauty medicine health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality. Under the brands "M1 Med Beauty" and "M1 Dental", a network of currently 24 outpatient specialist centres for beauty treatments and a specialist surgical clinic is operated. With six operating theatres and 35 beds, the Schlossklinik für Plastische und Ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. In addition, the group markets high-quality products to doctors, pharmacies and wholesalers. www.m1-kliniken.de

Contact
M1 Kliniken AG
Grünauer Str. 5
12557 Berlin
Phone: +49 (0)30 347 47 44 14
E-mail: ir@m1-kliniken.de


 


18.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

Eyemaxx 5,5%-Anleihe jetzt zeichnen!

Profitables Geschäftsmodell mit wachstums- und margenstarken Geschäftsfeldern in den Bereichen Wohnen und Gewerbe; Kernmärkte sind Deutschland und Österreich


öffentliches Angebot: vom 5. September 2019 bis zum 19. September 2019 (12:00 Uhr MESZ)

Emissionsvolumen: Bis zu 50 Mio. Euro

Umtauschangebot: Frist für Umtausch der Anleihe 2014/2020 bis 13. September 2019

WKN / ISIN: A2YPEZ/DE000A2YPEZ1

Zinszahlung/Zinszahlungsmodalitäten:5,5 % p.a (Kupon), (ICMA actual /actual), erste Zinszahlung am 24. September 2020v

GBC-Fokusbox

Fonds Research 2019: Dt. Mittelstandsanleihen FONDS bietet attraktive Anlagemöglichkeit

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter den Deutsche Mittelstandsanleihen FONDS (ISIN: LU0974225590), der eine qualitätsorientierte Strategie verfolgt und eine vielversprechende Anlagemöglichkeit in den deutschen Mittelstand bietet. Insbesondere vor dem Hintergrund des aktuellen Niedrigzinsniveaus sehen wir den Fonds als gute Chance, um attraktive Renditen zu erwirtschaften und dies verbunden mit einer traditionell niedrigen Fonds-Volatilität. Wir vergeben 5 von 5 GBC-Falken ein.

News im Fokus

Wirecard AG: Wirecard und SoftBank besiegeln strategische Kooperationsvereinbarung

18. September 2019, 07:15

Aktuelle Research-Studie

CO.DON AG

Original-Research: CO.DON AG (von Sphene Capital GmbH): Buy

18. September 2019